Novartis

Strategic intent

Novartis is a 'pure-play' innovative medicines company focused on developing and delivering high-value, transformative treatments in its core therapeutic areas of cardiovascular, renal and metabolic, immunology, neuroscience, and oncology. [1, 30]

Key market signals

• 2026-03: Acquired Excellergy, a developer of inhibitors for allergic diseases, for up to $2 billion. [31, 41]
• 2025-12: Reached an agreement with the US government aimed at lowering drug prices, including launching future medicines with comparable prices across high-income countries. [52]
• 2025-10: Announced agreement to acquire Avidity Biosciences for USD 12 billion to strengthen its neuroscience pipeline with RNA therapeutics, a deal expected to close in H1 2026. [41, 60]
• 2025-09: Acquired cardiovascular biotech Tourmaline Bio for $1.4 billion, gaining access to an IL-6 targeting program. [42]
• 2024-05: Acquired Mariana Oncology for $1 billion to bolster its radioligand therapy pipeline. [31, 33]

Financial health

• 2025 Full Year: Net Sales Growth of 8% (cc), Core Operating Income Growth of 14% (cc), Free Cash Flow of USD 17.6 billion. [1]
• 2025 Full Year: Net Sales USD 54.5 billion, Net Income USD 14.0 billion. [35]
• Q1 2026: Net Sales of USD 13.1 billion (-5% cc), Core Operating Income of USD 4.9 billion (-14% cc), Net Income of USD 3.2 billion (-13% cc). [5, 11, 20]

Impact & compliance

Legal & risks

In early 2026, a coalition of 42 states filed a new lawsuit against Novartis and its former subsidiary Sandoz, alleging a long-running conspiracy to fix prices, rig bids, and allocate markets for 31 generic drugs. [44] This follows the final approval in late 2023 of a $30 million settlement to resol

Classifications

🔒 Proprietary analysis

Proprietary Analysis — available with full access

Want the full analysis?

Get access to strategic fit scoring, cultural fit analysis, full forensic detail, and alignment dimensions.